Haematologica (Sep 2020)
Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
- Hui Wei,
- Chunlin Zhou,
- Dong Lin,
- Bingcheng Liu,
- Yan Li,
- Xingli Zhao,
- Shuning Wei,
- Benfa Gong,
- Kaiqi Liu,
- Xiaoyuan Gong,
- Yuntao Liu,
- Guangji Zhang,
- Jiayuan Chen,
- Junping Zhang,
- Jingjing Jin,
- Shaowei Qiu,
- Runxia Gu,
- Ying Wang,
- Yingchang Mi,
- Jianxiang Wang
Affiliations
- Hui Wei
- State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Chunlin Zhou
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Dong Lin
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Bingcheng Liu
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Yan Li
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Xingli Zhao
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Shuning Wei
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Benfa Gong
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Kaiqi Liu
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Xiaoyuan Gong
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Yuntao Liu
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Guangji Zhang
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Jiayuan Chen
- State Key Laboratory of Experimental Hematolog
- Junping Zhang
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Jingjing Jin
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Shaowei Qiu
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Runxia Gu
- Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Ying Wang
- National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Yingchang Mi
- State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- Jianxiang Wang
- State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
- DOI
- https://doi.org/10.3324/haematol.2020.267526
- Journal volume & issue
-
Vol. 106,
no. 5
Abstract
No abstracts available.